Mala
ria R
apid
Diag
nost
ic Te
st Pe
rform
ance
Re
sults
of W
HO p
rodu
ct te
sting
of m
alaria
RDT
s: Ro
und
4 (2
012)
Malaria Rapid Diagnostic Test Performance
Results of WHO product testing of malaria RDTs: Round 4 (2012)
Malaria Rapid Diagnostic Test Performance
Results of WHO product testing of malaria RDTs: 4 (2012)
WHO Library Cataloguing-in-Publication Data :Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 4 (2012).1.Malaria - diagnosis. 2.Antimalarials - therapeutic use. 3.Malaria - drug therapy. 4.Diagnostic tests, Routine. 5.Reagent kits, Diagnostic - utilization. 6.Sensitivity and specificity. I.UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. II.Centers for Disease Control (U.S.). III.Foundation for Innovative New Diagnostics.
ISBN 978 92 4 150472 0 (NLM classification: WC 750)
Copyright © World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases 2012
All rights reserved.The use of content from this health information product for all non-commercial education, training and information purposes is encouraged, including translation, quotation and reproduction, in any medium, but the content must not be changed and full acknowledgement of the source must be clearly stated. A copy of any resulting product with such content should be sent to TDR, World Health Organization, Avenue Appia, 1211 Geneva, Switzerland. TDR is a World Health Organization (WHO) executed UNICEF/UNDP/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases.
This information product is not for sale. The use of any information or content whatsoever from it for publicity or advertising, or for any commercial or income-generating purpose, is strictly prohibited. No elements of this information product, in part or in whole, may be used to promote any specific individual, entity or product, in any manner whatsoever.
The designations employed and the presentation of material in this health information product, including maps and other illustrative materials, do not imply the expression of any opinion whatsoever on the part of WHO, including TDR, or any parties cooperating in the production, concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delineation of frontiers and borders. Mention or depiction of any specific product or commercial enterprise does not imply endorsement or recommendation by WHO, including TDR, or any parties cooperating in the production, in preference to others of a similar nature not mentioned or depicted.
WHO, including TDR, make no warranties or representations regarding the content, presentation, appearance, completeness or accuracy in any medium and shall not be held liable for any damages whatsoever as a result of its use or application. WHO, including TDR, reserves the right to make updates and changes without notice and accepts no liability for any errors or omissions in this regard.
Any alteration to the original content brought about by display or access through different media is not the responsibility of WHO, including TDR. WHO, including TDR, accept no responsibility whatsoever for any inaccurate advice or information that is provided by sources reached via linkages or references to this health information product.
Layout: Bruno Duret
Printed in Italy
Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 4 (2012) I I I
Contents acknoWledgeMents ViiiabbreViations X
1. sUMMarY perforMance of Malaria rdts: WHo prodUct testing: roUnds 1–4 11.1. introduction 11.2. the WHo product testing programme 11.3. results of the evaluation 21.4. summary of outcomes 31.5. Use of these results 3
2. WHo Malaria rdt prodUct testing: roUnd 4 eXecUtiVe sUMMarY 172.1. introduction 172.2. the WHo product testing programme 172.3. results of the evaluation 182.4. Use of these results 18
3. backgroUnd 19
4. objectiVe 21
5. Materials and MetHods 215.1. test selection 215.2. outline of the product testing protocol 215.3. evaluation panels 245.4. rdt registration 255.5. specimen panel registration 255.6. test phases 255.7. performing rapid tests 255.8. interpretation of results 26
6. data ManageMent 27
7. QUalitY assUrance 27
8. etHical considerations 28
9. data analYsis 289.1. Measures of parasite detection: panel detection score
and positivity rates 289.2. false-positive results 28
9.2.1. incorrect species identification 299.2.2. false-positives from plasmodium-negative samples 29
9.3. band intensity 299.4. lot agreement 299.5. invalid tests 299.6. Heat (thermal) stability 29
10. laboratorY VersUs field-based Malaria rdt eValUations 30
Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 4 (2012)IV
11. resUlts 3111.1. summary 3111.2. phase 1 - p. falciparum culture panel 3611.3. phase 2 - Wild-type p. falciparum and p. vivax
and plasmodium spp. negative samples 3711.3.1. p. falciparum detection 3711.3.2. p. vivax detection 3811.3.3. combined detection of p. falciparum and p. vivax 3811.3.4. p. falciparum and p. vivax positivity rate 3911.3.5. band intensity 4011.3.6. false-positive rates 40
12. Heat stabilitY 4412.1. p. falciparum test lines 4712.2. pan-specific test lines 49
13. ease-of-Use description 51
14. discUssion of keY findings 5514.1. panel detection score (pds) and its relationship
to sensitivity 5514.2. false-positive rate and specificity 5614.3. Heat (thermal) stability 5714.4. ease-of-use description 5714.5. inter-lot variability 5814.6. target antigens and species 58
15. Using tHese resUlts to ensUre QUalitY of diagnosis in tHe field 5915.1. beyond procurement 5915.2. lot testing 59
16. conclUsions 60
17. references 60
anneXes 63annex 1: characteristics of rapid malaria tests in round 4 64annex 2: Malaria rdt guide to results interpretation 67annex 3: phase 1 results 82annex 4: phase 2 results 86annex 5a: selection of an appropriate rdt 118annex 5b: Malaria rdt field assessment and rdt anomalies 119annex 6: introducing rdt-based malaria diagnosis into national programmes 122
Reference to any company or product in this report, particularly in any of the figures or tables, does not in any way imply an endorsement, certification, warranty of fitness or recommendation by WHO of any company or product for any purpose, and does not imply preference over products of a similar nature that are not mentioned. WHO furthermore does not warrant that: (1) any list of companies or products is complete and/or error free; and/or that (2) any products listed are of acceptable quality, have obtained regulatory approval in any country, or that their use is otherwise in accordance with the national laws and regulations of any country, including but not limited to patent laws. Inclusion in this report does not furthermore imply any approval by WHO of the products in question (which is the sole prerogative of national authorities). Any lists of RDTs are not an exhaustive list of malaria RDTs. Such lists reflect those products which have been submitted for evaluation in Round 4 of the WHO Malaria RDT Product Testing Programme. The fact that certain products are not included in any list means that they have not or not yet been submitted for evaluation in the WHO Malaria RDT Product Testing Programme and does not indicate anything in respect of such products’ performance. WHO will not accept any liability or responsibility whatsoever for any injury, death, loss, damage, or other prejudice of any kind that may arise as a result of or in connection with the procurement, distribution and use of any product whatsoever included in this report. This report may not be used by manufacturers and suppliers for commercial or promotional purposes.
Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 4 (2012) V
figUres
Figure S1: MalariaRDTperformanceinPhase2ofRounds1–4againstwild-type(clinical)samplescontainingP. falciparum atlow(200)andhigh(2000or5000)parasitedensities(parasites/µl)andclean-negativesamples
Figure S2: MalariaRDTperformanceinPhase2ofRounds1–4againstwild-type(clinical)samplescontainingP. vivax atlow(200)andhigh(2000or5000)parasitedensities(parasites/µl)andclean-negativesamples
Figure 1: Modeofactionofantigen-detectingmalariaRDTs
Figure 2: Networkofspecimencollection,characterizationandtestingsites
Figure 3: MalariaRDTProductTestingOverview
Figure 4a: OriginofPhase2P. falciparumwild-type(clinical)samples
Figure 4b: OriginofPhase2P. vivaxwild-type(clinical)samples
Figure 5: Testingprocedureandcalculationof‘paneldetectionscore’andbandintensityforProductAagainstasampledensityof200parasites/µl
Figure 6: Testingprocedureandcalculationof‘paneldetectionscore’andbandintensityforProductAagainstasampledensityof2000parasites/µl
Figure 7: Phase1P. falciparumpaneldetectionscoreofmalariaRDTsatlow(200)andhigh(2000)parasitedensities(parasites/µl)accordingtotargetantigentype(HRP2orpLDH)
Figure 8: Phase2P. falciparumpaneldetectionscoreofmalariaRDTsatlow(200)andhigh(2000)parasitedensity(parasites/µl)accordingtotargetantigentype(HRP2orpLDH)
Figure 9: Phase2P. vivaxpaneldetectionscoreofmalariaRDTsatlow(200)andhigh(2000)parasitedensities(parasites/µl)accordingtotargetantigentype(aldolase,pLDH)
Figure 10: Phase2P. falciparumpaneldetectionscoreandpositivityrateat200parasites/µl
Figure 11: Phase2P. vivaxpaneldetectionscoreandpositivityrateat200parasites/µl
Figure 12: Phase2P. falciparum(P. falciparumtestline)false-positiverateagainstclean-negativesamples
Figure 13: Phase2Plasmodiumspp.(panorP. vivax /Pvom testline)false-positiverateagainstclean-negativesamples
Figure 14: Phase2P. falciparumfalse-positiverateversusP. falciparumpaneldetectionscoreatlow(200)parasitedensity(parasites/µl)
Figure 15: Phase2P. vivaxfalse-positiverateversusP. vivaxpaneldetectionscoreatlow(200)parasitedensity(parasites/µl)
Figure 16: HeatstabilityofP. falciparum-specifictestlineofP. falciparum-onlytestsagainstalowdensityP. falciparumsample(200parasites/µl).Positivityrateatbaseline,andafter60daysincubation
Figure 17: HeatstabilityofP. falciparum-specifictestlineofP. falciparum-onlytestsagainstahighdensityP. falciparumsample(2000parasites/µl).Positivityrateatbaseline,andafter60daysincubation
Figure 18: HeatstabilityofP. falciparum-specifictestlineincombinationtestsagainstalowdensityP. falciparum sample(200parasites/µl).Positivityrateatbaseline,andafter60daysincubation
Figure 19: HeatstabilityofP. falciparumspecifictestlineincombinationtestsagainstahighdensityP. falciparum sample(2000parasites/µl).Positivityrateatbaseline,andafter60daysincubation
Figure 20: Heatstabilityofpan-lineofpan-specifictestsagainstalowdensityP. falciparumsample(200parasites/µl).Positivityrateatbaseline,andafter60daysincubation
Figure 21: Heatstabilityofpan-lineofpan-specifictestsagainstahighdensityP. falciparumsample(2000parasites/µl).Positivityrateatbaseline,andafter60daysincubation
Figure 22: Heatstabilityofpan-lineofcombinationtestsagainstalowdensityP. falciparumsample(200parasites/µl).Positivityrateatbaseline,andafter60daysincubation
Figure 23: Heatstabilityofpan-lineofcombinationtestsagainstahighdensityP. falciparumsample(2000parasites/µl).Positivityrateatbaseline,andafter60daysincubation
Figure A5.1: HowtoselectofanappropriateRDT
Figure A5.2: MalariaRDTanomaliesencounteredinproductionlots
Figure A6.1: ExampleofmalariaRDTimplementationstepsandtimeline
Figure A6.2: Componentsofthebudgetforamalariadiagnosisprogramme
Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 4 (2012)VI
tables
Table S1: MalariaRDTPhase2performanceinRounds1–4againstwild-type(clinical)samplescontainingP. falciparum and P. vivax atlow(200)andhigh(2000or5000)parasitedensities(parasites/µl)andclean-negativesamples
Table S2: MalariaRDTRounds1–4heatstabilityresultsonacultured P. falciparum sampleatlow(200)andhigh(2000)parasitedensity(parasites/µl).Positivityrateatbaseline,andafter60daysincubationat35°Cand45°C
Table S3: Productresubmissions:WHOMalariaRDTProductTesting(Rounds1–4)
Table 1: ManufacturersandproductsacceptedintoRound4ofWHOMalariaRDTProductTestingProgramme
Table 2: CharacteristicsofPlasmodiumspp.negativespecimens
Table 3: SummaryPhase1performanceof48malariaRDTsagainst20culturedP. falciparumlinesatlow(200)andhigh(2000)parasitedensities(parasites/µl)
Table 4: SummaryPhase2performanceof46malariaRDTsagainstwild-type(clinical)P. falciparumandP. vivaxsamplesatlow(200)andhigh(2000)parasitedensities(parasites/µl)andPlasmodiumspp.negativesamples
Table 5: Heatstabilitytestingresultsfor46malariaRDTsonaculturedP. falciparumsampleatlow(200)andhigh(2000)parasitedensities(parasites/µl).Positivityrateatbaseline,andafter60daysincubationat35°Cand45°C
Table 6: Ease-of-usedescriptionof48malariaRDTs
Table A3.1: LotvariabilityinpositiveresultsagainstP. falciparumculturesamplesatlow(200)andhigh(2000or5000)parasitedensities(parasites/µl)
Table A3.2: Distributionoftestbandintensityscores(0–4)againstPhase1P. falciparumculturedparasitesatlow(200)andhigh(2000)parasitedensities(parasites/µl)
Table A4.1: LotvariabilityinpositiveresultsagainstPhase2wild-typeP. falciparumandP. vivaxsamplesatlow(200)andhigh(2000)parasitedensities(parasites/µl)
Table A4.2: Distributionoftestbandintensity(0–4)scoresagainstPhase2wild-typeP. falciparumsamplesatlow(200)andhigh(2000)parasitedensities(parasites/µl)
Table A4.3: DistributionofPan/Pvtestbandintensity(0–4)scoresforPhase2wild-typeP. vivaxsamplesatlow(200)andhigh(2000)parasitedensities(parasites/µl)
Table A4.4: PaneldetectionscoreofPhase2wild-typeP. falciparuminlow(200)andhigh(2000)parasitedensities(parasites/µl)bycontinent
Table A4.5: Phase2P. falciparumtestlinefalse-positiveratesforwild-typeP. vivaxsamplesatlow(200)andhigh(2000)parasitedensities(parasites/µl)
Table A4.6: Phase2Pan(orP. vivax)testlinefalse-positiveratefornon-Pfinfectiononwild-typeP. falciparumsamplesatlow(200)andhigh(2000)parasitedensities(parasites/µl)
Table A4.7: Phase2false-positiverateforP. falciparumtestlineresultsonallmalaria-negativesamples
Table A4.8: Phase2false-positiverateforP. falciparuminsamplescontainingspecificnon-malarialinfectiouspathogens
Table A4.9: Phase2false-positiverateforP. falciparuminsamplescontainingpotentiallycross-reactingbloodimmu-nologicalfactors
Table A4.10: Phase2false-positiverateforpan/P. vivax/Pvomtestlineresultsonallmalaria-negativesamples
Table A4.11: HeatstabilitytestingresultsforP. falciparum(orpan)testlineonaP. falciparumsampleatlowparasitedensity(200parasites/µl).Positivityrateatbaseline,andafter60daysincubationat4°C,35°Cand45°C
Table A4.11a: HeatstabilitytestingresultsforpantestlineofcombinationRDTsonaP. falciparumsampleatlowparasitedensity(200parasites/µl).Positivityrateatbaseline,andafter60daysincubationat4°C,35°Cand45°C
Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 4 (2012) VII
Table A4.12: HeatstabilitytestingresultsforP. falciparum(orpan)testlineonaP. falciparumsampleathighparasitedensity(2000parasites/µl).Positivityrateatbaseline,andafter60daysincubationat4°C,35°Cand45°C
Table A4.12a: HeatstabilitytestingresultsforpantestlineofcombinationRDTsonaP. falciparumsampleathighparasitedensity(2000parasites/µl).Positivityrateatbaseline,andafter60daysincubationat4°C,35°Cand45°C
Table A4.13: HeatstabilitytestingresultsforP. falciparum(orpan)testlineonparasite-negativesamples.Positivityrateatbaseline,andafter60daysincubationat4°C,35°Cand45°C
Table A4.13a: HeatstabilitytestingresultsforpantestlineofcombinationRDTsonparasite-negativesamples.Positivityrateatbaseline,andafter60daysincubationat4°C,35°Cand45°C
Table A5.1 MalariaRDTfieldassessmentofpackaging,safetyandease-of-usetoguideproductselection
Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 4 (2012)VIII
acknoWledgeMents
TheevaluationdescribedinthisreportwasajointprojectoftheWorldHealthOrganization(WHO)GlobalMalariaProgramme(GMP),theFoundationforInnovativeNewDiagnostics(FIND),theSpecialProgrammeforResearchandTraininginTropicalDiseasessponsoredbyUNICEF,UNDP,WorldBankandWHO(TDR)andtheUSCentersforDiseaseControlandPrevention(CDC),undertheWHO-FINDMalariaRDTEvaluationProgramme.TheprojectwasfinancedbyFIND,throughgrantsfromtheBillandMelindaGatesFoundation,theGlobalFundtofightAIDS,TuberculosisandMalaria,theUnitedStatesAgencyforInternationalDevelopment(USAID),andtheUKDepartmentforInternationalDevelopment(DFID),andbyTDR.Theprojectwouldnothavebeenpossiblewithoutthecooperationandsupportofthespecimencollectionsites,andthespecimencharacterizationlaboratoriesmentionedherein,andacknowledgesthetechnicaladvicefrommanymalariadiagnosticmanufacturersanddevelopersinthedevelopmentoftheprogramme.ThisreportonRound4ofWHOMalariaRDTProductTestingwascompiledbyJaneCunningham(WHO/GMP,Switzerland)andDavidBell(FoundationforInnovativeNewDiagnostics(FIND),Switzerland)
TheMalariaRDTEvaluationProgrammeofWHO,TDRandFINDisgratefultoallthosewhocontributedtotheconductoftheevaluationandpreparationofthisRound4report.
Salim Abdullah IfakaraHealthResearchandDevelopmentCentre,UnitedRepublicofTanzania
Yong Ah USCentersforDiseaseControlandPrevention/NationalCenterforGlobalHealth/DivisionofMalariaandParasiticDiseases,UnitedStatesofAmerica
Audrey Albertini FoundationforInnovativeNewDiagnostics(FIND),Switzerland
Frederic Ariey InstitutPasteur,Cambodia
John Barnwell USCentersforDiseaseControlandPrevention/NationalCenterforGlobalHealth/DivisionofMalariaandParasiticDiseases,UnitedStatesofAmerica
John Bligh HospitalforTropicalDiseases,UnitedKingdomofGreatBritainandNorthernIreland
David Bell FoundationforInnovativeNewDiagnostics(FIND),Switzerland
Andrea Bosman WorldHealthOrganization/GlobalMalariaProgramme,Geneva,Switzerland
Sandra Buisson HospitalforTropicalDiseases,UnitedKingdomofGreatBritainandNorthernIreland
Debora Casandra USCentersforDiseaseControlandPrevention/NationalCenterforGlobalHealth/DivisionofMalariaandParasiticDiseases,UnitedStatesofAmerica
Qin Cheng ArmyMalariaInstitute,Australia
Peter Chiodini HospitalforTropicalDiseases,UnitedKingdomofGreatBritainandNorthernIreland
Jane Cunningham TDR,SpecialProgrammeforResearchandTraininginTropicalDiseases,Switzerland
Chona Daga ResearchInstituteofTropicalMedicine,ThePhilippines
Linda Dantes WHO–RegionalOfficefortheWesternPacific,ThePhilippines
Djibrine Djalle InstitutPasteurBangui,CentralAfricanRepublic
Katie Downey USCentersforDiseaseControlandPrevention/NationalCenterforGlobalHealth/DivisionofMalariaandParasiticDiseases,UnitedStatesofAmerica
Babacar Faye UniversitéCheikhAntaDIOP,Senegal
Nahla Gadalla HospitalforTropicalDiseases,UnitedKingdomofGreatBritainandNorthernIreland
Dionicia Gamboa UniversidadPeruanaCayetanoHerediaInstitutodeMedicinaTropical,Peru
Cyrus Garay ResearchInstituteofTropicalMedicine,ThePhilippines
Michelle Gatton QueenslandInstituteofMedicalResearch,Australia
Jeffrey Glenn USCentersforDiseaseControlandPrevention/NationalCenterforGlobalHealth/DivisionofMalariaandParasiticDiseases,UnitedStatesofAmerica
Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 4 (2012) IX
Iveth Gonzalez FoundationforInnovativeNewDiagnostics(FIND),Switzerland
Sandra Incardona FoundationforInnovativeNewDiagnostics(FIND),Switzerland
Cara Kosack MédecinsSansFrontières,TheNetherlands
Myat Phone Kyaw DepartmentofMedicalResearch,Myanmar
Jennifer Luchavez ResearchInstituteofTropicalMedicine,ThePhilippines
Lorraine Mationg ResearchInstituteofTropicalMedicine,ThePhilippines
James McCarthy QueenslandInstituteofMedicalResearch,UniversityofQueensland,Australia
Didier Menard InstitutPasteurdeMadagascar,Madagascar;InstitutPasteur,Cambodia
Claribel Murillo CentroInternacionaldeEntrenamientoeInvestigacionesMédicas(CIDEIM),Colombia
Sina Nhem InstitutPasteur/NationalMalariaCentre(CNM),Cambodia
Bernhards Ogutu KenyaMedicalResearchInstitute(KEMRI),Kenya
Pamela Onyor KenyaMedicalResearchInstitute(KEMRI),Kenya
Wellington Oyibo UniversityofLagos,Nigeria
Anita Pelecanos QueenslandInstituteofMedicalResearch,Australia
Mark Perkins FoundationforInnovativeNewDiagnostics(FIND),Switzerland
Roxanne Rees-Channer Consultant(FIND),HospitalforTropicalDiseases,UnitedKingdomofGreatBritainandNorthernIreland
Muth Sinuon NationalMalariaCentre(CNM),Cambodia
Man Somnang InstitutPasteur/NationalMalariaCentre(CNM),Cambodia
Julie Vercruysse FoundationforInnovativeNewDiagnostics(FIND),Switzerland
Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 4 (2012)X
abbreViations
ACT Artemisinin-basedcombinationtherapy
AMI ArmyMalariaInstitute
CDC UnitedStatesCentersforDiseaseControlandPrevention
CLIA ClinicalLaboratoryImprovementAmendments
DFID UKDepartmentforOverseasDevelopment
FIND FoundationforInnovativeNewDiagnostics
FP False-positive
HRP2 Histidine-richprotein2
HTD HospitalforTropicalDiseases
ISO InternationalOrganizationforStandardization
PCR Polymerasechainreaction
PDS Paneldetectionscore
pLDH Plasmodiumlactatedehydrogenase
Pf Plasmodium falciparum
Pv Plasmodium vivax
Pvom Plasmodium vivax, ovale, malariae
PR Positivity rate
p/µL Parasitespermicrolitre
QA Qualityassurance
QC Qualitycontrol
QMS Qualitymanagementsystems
RDT Rapiddiagnostictest(forthepurposesofthisreport,thisreferstoimmunochromatographiclateralflowdevicesforthedetectionofmalariaparasiteantigens)
SOP StandardOperatingProcedure
TDR SpecialProgrammeforResearchandTraininginTropicalDiseasessponsoredbyUNICEF,UNDP,WorldBankandWHO
UN UnitedNations
USA UnitedStatesofAmerica
USAID UnitedStatesAgencyforInternationalDevelopment
WPRO WesternPacificRegionalOffice
WHO WorldHealthOrganization
sUM
Mar
Y r
oU
nd
s 1-
4
1Malaria rapid diagnostic test perforMance – summary results of WHo product testing of malaria rdts: round 1-4 (2008-2012)
1. sUMMarY perforMance of Malaria rdts: WHo prodUct testing: roUnds 1–4
1.1. introductionTheWorldHealthOrganizationestimatesthathalftheworld’spopulationisatriskofmalaria,withanestimated216millionpeople(range149–274million)developingclinicalmalaria in2010(81%inAfrica),and655,000deaths(range537,000–907,000)duetomalaria(91%inAfrica,mostbeingchildren).Malariaremainsendemicin106countries,andwhileparasite-baseddiagnosisisincreasing,mostsuspectedcasesofmalariaarestillnotproperlyconfirmed,resultinginover-useofanti-malarialdrugsandpoordiseasemonitoring1.
WHOrecommendsthatmalariacasemanagementbebasedonparasite-baseddiagnosisinallcases2.Theuseofantigen-detectingrapiddiagnostictests(RDTs)formsavitalpartofthisstrategy,formingthebackboneofexpansionofaccesstomalariadiagnosisbyprovidingparasite-baseddiagnosisinareaswheregoodqualitymicroscopycannotbemaintained.ThenumberofRDTsavailable,andthescaleoftheiruse,hasrapidlyincreasedoverthepastfewyears.However,limitationsofcomparativefieldtrialsandtheheterogeneousnatureofmalariatransmissionandepidemiologyhaslimitedtheavailabilityofgoodqualityperformancedatathatnationalmalariaprogrammesrequiretomakeinformeddecisionsonprocurementandimplementation,andlimitstheabilitytoextrapolateresultsoffieldtrialstodifferentpopulationsandtimeperiods.Tothisend,in2006,theWorldHealthOrganization(WHO),SpecialProgrammeforResearchandTraininginTropicalDiseases(TDR)andtheFoundationforInnovativeNewDiagnostics(FIND)launchedanevalua-tionprogrammetoassessthecomparativeperformanceofcommerciallyavailablemalariaRDTs.Currently,thesedataareguidingprocurementdecisionswhichareinturnshiftingmarketstowardsbetter-performingtests1andhelpingtodriveoverallimprovementinthequalityofmanufacturing.TheresultsofWHOMalariaRDTProductTestinghavebeenpublishedannuallysince2009andformthebasisofprocurementcriteriaofWHO,otherUNagencies,theGlobalFundandnationalgovernments.
ThisSummarypresentsanoverviewoftheresultsofthefirstthroughfourthroundsofWHOMalariaRDTProductTestingandispublishedinconjunctionwiththereleaseofthefullreportonRound4.Theresultsofthefourroundsoftestingshouldbeconsideredasasingledataset.Separate
1 World Malaria Report 2011.Geneva,WorldHealthOrganization,20112 Guidelines for the Treatment of Malaria, Second Edition.Geneva,
WorldHealthOrganization,2010(ISBN9789241547925)
fullreportsofallroundsshouldbeconsultedforfurtherdetailonproductperformance,andontheinterpretationanduseoftheseresults.
1.2. the WHo product testing programmeTheRDTevaluationssummarizedherewereperformedasacollaborationbetweenWHO,TDR,FIND,theUSCentersforDiseaseControlandPrevention(CDC)andotherpartners3.AllcompaniesmanufacturingunderISO13485:2003QualitySystemStandardwereinvitedtosubmitalimitednumberofproducts(2–3)forevaluationundertheprogramme.Inthefirstroundoftesting,41productsfrom21manufacturerswereevaluatedagainstpreparedbloodpanelsofculturedPlasmodium falciparumparasites,while29,50and48productsfrom13,23and27manufacturerswereevaluatedinRound2,3and4,respectively.Manymanufacturershavedecidedtovoluntarilyre-submitproductstooneormoreroundsoftesting,including1,23and13resubmissionsinRound2,3and4,respectively(TableS3).Ofthese168totalproducts,164progressedtotestingagainstpanelsofpatient-derivedP. falciparumandP. vivaxparasites,andaparasite-negativepanel.Thermalstabilitywasassessedaftertwomonthsofstorageatelevatedtemperatureandhumidity,andadescriptiveease-of-useassessmentwasrecorded.Ofthe164fullyevaluatedproducts,21havebeenevaluatedtwice,and8havebeenevaluatedthreetimesbetweenRounds1-4.Ofthe128uniqueproductstestedbytheprogramme,35detectP. falciparumalone,83detectanddifferentiateP. falciparumfromnon-P. falciparummalaria(eitherpan-specificorspecies-specific(Pv,Pvom),9detectP. falciparumandnon-P. falciparummalariawithoutdistinguishingbetweenthem,andoneproductwasdesignedtodetectP. vivaxonly.Manufacturerssubmittedtwolotsofeachproductforevaluation.Wherethesameproducts4havebeenre-submittedinsubsequentroundsoftesting,thelatterresultsreplacethosepublishedfromtheearlierround.Thus,theperformanceofmanytestsintheresultsbelowdifferfromthosepublishedintheRounds1–3reports.
Theevaluationisdesignedtoprovidecomparativedataontheperformanceofthesubmittedproductionlotsofeachproduct.SuchdatawillbeusedtoguideprocurementdecisionsofWHOandotherUNagenciesandnationalgovernments.
3 SeefullreportsofRounds1–4forfulllistofcollaboratingpartners.4 Informal Consultation on Laboratory Methods for Quality Assurance
of Malaria Rapid Diagnostic Tests.20-22July2004.Manila.WHORegionalOfficefortheWesternPacific.2004.(RS/2004/GE/26(PHL)
2 Malaria rapid diagnostic test perforMance – summary results of WHo product testing of malaria rdts: round 1-4 (2008-2012)
ProducttestingispartofacontinuingprogrammeofworktoimprovethequalityofRDTsthatareused,andtosupportbroadimplementationofreliablemalariadiagnosisinareaswheremalariaisprevalent.AfifthroundofproducttestingwillbegininJanuary2013.
1.3. results of the evaluationTheresults(summarizedinFiguresS1andS2andTablesS1andS2)providecomparativedataontwolotsofproductsagainstapanelofparasitesamplesdilutedtoalowparasitedensity(200parasites/µl)andahigherparasitedensity(2000or5000parasites/µl).Theformeriswellbelowthemeanparasitedensityfoundinmanypopulationswithendemicmalaria,andconsideredclosetothethresholdthattestsmustdetecttoreliablyidentifyclinicalmalariainmanysettings1.Forthepurposesofthisreport,themainmeasureofperform-anceisthe‘paneldetectionscore(PDS)’2;thepercentageofmalariasamplesinthepanelgivingapositiveresultbytwoRDTsperlotatthelowerparasitedensity,andasingleRDTperlotatthehigherparasitedensity.Thus,itisnotameasureofRDTclinicalsensitivity,orpositivityrateagainstthepanelbutratheracombinedmeasureofpositivityrate,alongwithinter-testandinter-lotconsistency.Thefiguresalsoshowthefalse-positiveratesagainstbloodsamplescontainingnomalariaparasitesorknownmarkersofotherdiseases,andtherateatwhichinvalidresultsoccurred.
TheclinicalsensitivityofaRDTtodetectmalariaishighlydependentonthelocalconditions,includingparasitedensityinthetargetpopulation.Sensitivityofatestwillthereforevaryamongpopulationswithdifferinglevelsoftransmis-sion,astheirdifferentlevelsofimmunityaffectthepara-sitedensityatwhichtheyexhibitsymptomswarrantingadiagnostictest.Wheretransmissionratesarelow,parasitedensitiesinpeoplewithsymptomsofmalariaarelikelytobelower,resultingintestshavingalowersensitivity.Forthisreason,testperformanceat200parasites/µlisparticularlyimportant.TheresultsinthisreportshowcomparativeperformanceamongRDTs,andgiveanindicationofwhichproductsarelikelytoprovidehighersensitivityinthefield,particularlyinpopulationswithlow-densityinfections.
Ingeneral,ascountriesreducemalariaprevalenceandevenmovetowardsmalariaelimination,detectionoflowparasitedensitiesbecomesincreasinglyimportantincasemanage-ment.Asthedetectionrateat2000parasites/µlindicates,thesensitivityofmanyoftheseproductswillbesimilarinpopulationswithhigherparasitedensities,althoughasubsetofanypopulationwillincludevulnerableindividualswhomaydevelopillnessatlowparasitedensities(e.g.youngchildren,pregnantwomen,thosewellprotectedbybednets)andmustalwaysbetakenintoaccountwheninterpretingRDTresults.AnimportantcaveatwhenpredictingfieldsensitivityfromthePDSprovidedinthisreportisthatthepanelsusedinthis
1 Parasitological Confirmation of Malaria Diagnosis. ReportofaWHOtechnicalconsultationGeneva,6–8October2009. Geneva,WorldHealthOrganization,2010.(ISBN9789241599412)
2 Termed‘DetectionRate’inthefullreportofRound1,publishedin2009.SeetheRound4reportforafullexplanationofthepaneldetectionscore(PDS).
evaluationonlyincludeparasitesknowntoexpressthetargetantigens.Whilenon-expressionofthetargetantigenshasnotbeenrecordedforaldolaseorpLDH,itisknownthatparasitesinfectingpeopleinsomeareasofSouthAmericadonotexpressHRP23.InareaswhereHRP2-deletedparasitesexist,HRP2-detectingtestswillhavegreatlyreducedsensitivityorbeincapableofdetectingP. falciparum.Insuchpopulations,onlytestsdetectingpLDHinP. falciparumparasiteswillbeeffectiveindiagnosingfalciparummalaria.
Heatstability(summarizedinTableS2)isvitaltomaintainingsensitivityofthetestinthefield.Asaresult,forprocurement,itisessentialthatcarefulconsiderationbegiventostabilityresultstoensurethatproductstobeusedinareaswithhightemperaturesoftransportandstoragehavedemonstratedstabilityintheproducttestingprogramme.Requirementswillvarybetweencountries:forexample,iftestsaretobedeployedinareaswheretemperaturesrarelyriseabove30°C,lessemphasismaybeplacedonstabilityathightemperaturescomparedtootheraspectsoftestquality.
Ease-of-userequirementswillalsovary,dependingontheextentoftrainingandtheworkenvironmentoftheend-users.Particularlyinprimaryhealthcaresettings,thesimplerthetests,theeasieritwillbetoavoiderrorsinpreparationandinterpretation.
Detailedresultsoftheevaluationscanbefoundinthereportsofeachevaluation,4andatwww.wpro.who.int/sites/rdt.WHOprovidesguidanceontheprocurementandimplementationofmalariaRDTs5,6.Furthermore,aninteractiveguidetoassistinselectingproductswithperformancecharacteristicsmostsuitableforaparticularcountryhealthprogrammeisfoundontheFINDwebsite.7
3 Gamboa,D.,M.F.Ho,etal. A large proportion of P. falciparum isolates in the Amazon region of Peru lack pfhrp2 and pfhrp3: implications for malaria rapid diagnostic tests. PLoS One,2010:5(1):e8091.
4 Malaria Rapid Diagnostic Test Performance : Results of WHO product testing of malaria RDTs: Round 1 (2008).Geneva,WorldHealthOrganization,2009.ISBN9789241598071;Malaria Rapid Diagnostic Test Performance : Results of WHO product testing of malaria RDTs: Round 2 (2009). Geneva,WorldHealthOrganization,2010.ISBN9789241599467;Malaria Rapid Diagnostic Test Performance : Results of WHO product testing of malaria RDTs: Round 3 (2010-11).Geneva,WorldHealthOrganization,2011.ISBN9789241502566.
5 Good practices for selecting and procuring rapid diagnostic tests for malaria.Geneva,WorldHealthOrganization , 2011(ISBN9789241501125)
6 Universal Access to Malaria Diagnostic Testing: An operational manual.Geneva,WorldHealthOrganization,2011(ISBN978924150209)
7 MalariaRDTInteractiveGuide:http://www.finddiagnostics.org/programs/malaria-afs/malaria/rdt_quality_control/product_testing/interactive-guide/index.jsp
sUM
Mar
Y r
oU
nd
s 1-
4
3Malaria rapid diagnostic test perforMance – summary results of WHo product testing of malaria rdts: round 1-4 (2008-2012)
1.4. summary of outcomesThislaboratory-basedevaluationprovidesacomparativemeasureofRDTperformanceinastandardizedwaytodistinguishbetweenwellandpoorlyperformingteststoinformprocurementdecisionsofmalariacontrolprogrammesandguideUNprocurementpolicy.
Overall,thegainsnotedintheperformanceofproductsre-submittedtoRound3wereseenagaininRound4forseveralproducts(TableS3),indicatingproductimprovementbythemanufacturers.Furthermore,inRound4thepropor-tionoftestsachievingaPDS(>75%)at200parasites/µliscomparabletoRound3forP. falciparumat73.9%andforP. vivax,theproportionis47.2%,representinganimprove-mentoverRounds1and3combined(36.7%).
SeveralRDTsfromthefourroundsoftestingdemonstratedconsistentdetectionofmalariaatlowparasitedensities(200parasites/µl),havelowfalse-positiverates,arestableattropicaltemperatures,arerelativelyeasytouse,andcandetectP. falciparum,P. vivaxinfections,orboth.
Performanceamongproductsvariedwidelyatlowparasitedensity(200parasites/µl);however,themajorityofproductsshowedahighlevelofdetectionat2000or5000parasites/µl.
P. falciparumteststargetingHRP2antigendemonstratedthehighestdetectionrates.InRound4,bothteststargetingpf-pLDHfordetectionofP. falciparuminfectiondidnotpassPhase1.Thus,therangeofchoiceforwell-performingpLDHbasedP. falciparumtestsremainslimited,asitdoesforpan-onlyspecifictests.
Testperformancesometimesvariedbetweenlots,andwidelybetweensimilarproducts,confirmingtheadvisabilityoflot-testingpost-purchaseandpriortouseinthefield.
Theresultsunderscoretheneedformanufacturerstohaveadequatereferencematerialsforproductdevelopmentandlot-release.TheWHO-FINDMalariaRDTEvaluationProgramme,incollaborationwiththeCDC,offersqualitystandardpanelsofP. falciparumisolatestomanufacturerstoassistinthisprocessandisplanningtotransitiontomalariarecombinantantigenspanelsbytheendof2014.
1.5. Use of these resultsAccuratediagnosisisvitaltogoodmalariacasemanagement,whetherbasedonmicroscopyorRDTs.Theresultsofthisreportshouldbeusedtoshort-listRDTsforprocurementforuseinsettingswheregoodmicroscopyisnotavailableorappropriate.Additionally,itisimperativethatprocurementdecisionsbasedontheseresultstakeintoconsiderationlocalconditionsofmalariatransmissionandillnesswherethetestswillbeused(e.g.Plasmodiumspecies,targetantigenvaria-tion,parasitedensities,climate),aswellasotherimportantconsiderations,includingfield-basedease-of-useassess-ments,andtraining/retrainingrequirements.Furthermore,inordertoensurethatthehighperformancedemonstratedbythelotsevaluatedintheproducttestingprogrammeismaintained,itisrecommendedthateachlotofRDTsisalsotestedinastandardizedwaypriortodispersaltothefield1.ProcurementofRDTsmustnotoccurwithoutprogrammaticandinfrastructurepreparationforproperuse,includingsupplychainmanagement,trainingontestusageanddisposal,andtrainingonpatientmanagementinresponsetoresults.Themainreportprovidesanalgorithm(Annex5a)toassistinthisdecision-makingprocessandcomprehensiveguidanceonseveralaspectsofprocurementcanbefoundin‘Good Practices for selecting and procuring rapid diagnostic tests for malaria’2.
1 TheWHO-FINDMalariaRDTEvaluationProgrammeprovideslot-testingcapacityinanumberofregionallaboratoriesfreeofcharge,[email protected]@finddiagnostics.org.
2 Good Practices for selecting and procuring rapid diagnostic tests for malaria, Geneva, World Health Organization, 2011(ISBN9789241501125)
mailto:Malaria_rdt%40who.int?subject=mailto:info%40finddiagnostics.org?subject=
4 Malaria rapid diagnostic test perforMance – summary results of WHo product testing of malaria rdts: round 1-4 (2008-2012)
Figure S1: Malaria RDT performance in Phase 2 of Rounds 1-4 against wild type (clinical) samples containing P. falciparum at low (200) and high (2000–5000) parasite densities (parasites/µl) and clean-negative samples
a Panel detection score - A sample is considered detected only if all RDTs from both lots read by the first technician, at minimum specified reading time, are positive. b Clean-negative - blood samples from healthy volunteers with no known current illness or blood abnormality. * Indicates tests that also detect other non-P. falciparum parasites
Firs
t Res
pons
e® M
alar
ia A
g H
RP2
I13
FRC
30H
umas
is M
alar
ia P
.f/Pa
n An
tigen
Tes
t AM
AL-7
025
Para
scre
en™
Dev
ice
- Rap
id te
st f
or M
alar
ia P
an/P
f 503
1002
5C
ore
Mal
aria
Pan
Pf M
AL-1
9002
4BI
OC
RED
IT M
alar
ia p
f(HR
P II)
HR
0100
Car
eSta
rt™ M
alar
ia H
RP2
(Pf)
G01
41C
areS
tart™
Mal
aria
HR
P2/p
LDH
Pf t
est G
0181
Falc
ivax
™ R
apid
Tes
t for
Mal
aria
Pv/
Pf 5
0300
025
diag
nost
icks
MAL
ARIA
(Pan
/Pf)
Cas
sette
MPN
FWBC
1007
.4C
ore™
Mal
aria
Pv/
Pf M
AL-1
9002
2Ad
vant
age
P.f.
Mal
aria
Car
d IR
0160
25C
areS
tart™
Mal
aria
HR
P2/p
LDH
(Pf/P
AN) C
OM
BO G
0131
SD B
IOLI
NE
Mal
aria
Ag
Pf 0
5FK5
0C
ore™
Mal
aria
Pf
MAL
-190
020
SD B
IOLI
NE
Mal
aria
Ag
Pf/ P
f/ Pv
05F
K100
SD B
IOLI
NE
Mal
aria
Ag
Pf/P
v 05
FK80
Para
chec
k® P
f - R
apid
test
for P
. fal
cipa
rum
Mal
aria
Dev
ice
Ver.3
303
0102
5M
alar
ia p
f (H
RP
II) /
(PAN
-pLD
H) A
ntig
en D
etec
tion
Test
Dev
ice
MFV
-124
RIN
D O
NE
STEP
MAL
ARIA
AN
TIG
EN P
.f/Pa
n TE
ST 5
35-1
0Fi
rstS
ign™
Mal
aria
Pf 2
100C
B-25
One
Ste
p M
alar
ia P
.F T
est (
cass
ette
) 5
2235
2Ad
vanc
ed Q
ualit
y™ O
ne S
tep
Mal
aria
P.f
Test
ITP
1100
2TC
40BI
ON
OTE
MAL
ARIA
P.f.
& Pa
n Ag
Rap
id T
est K
it R
G19
-08
diag
nost
icks
MAL
ARIA
(Pan
/Pv/
Pf) C
asse
tte M
PNVF
C10
07.5
Imm
unoq
uick
Mal
aria
+4
0506
_K25
Para
max
-3 R
apid
Tes
t for
Mal
aria
Pan
/Pv/
Pf (d
evic
e) 5
0320
025
SD B
IOLI
NE
Mal
aria
Ag
P.f/P
an
05FK
60C
ore™
Mal
aria
Pan
/Pv/
Pf M
AL-1
9002
6BI
ON
OTE
MAL
ARIA
P.f.
& P.
v. A
g R
apid
Tes
t Kit
RG
19-1
2N
anoS
ign
Mal
aria
Pf/P
an A
g 3.
0 R
MAP
10H
umas
is M
alar
ia P
.f/P.
v An
tigen
Tes
t AM
FV-7
025
RAP
ID 1
-2-3
® H
EMA
CAS
SETT
E M
ALAR
IA P
F/PV
TES
T M
AL-P
FV-C
AS/2
5(10
0)M
alar
ia P
lasm
odiu
m fa
lcip
arum
Rap
id te
st D
evic
e (W
hole
blo
od) I
MA-
402
Car
eSta
rt™ M
alar
ia p
LDH
(PAN
) G01
11O
nSig
ht™
- Pa
raQ
uick
-2 (P
v,Pf
) Mal
aria
Tes
t 537
-25-
DB
Imm
unoq
uick
Mal
aria
Fal
cipa
rum
050
2_K2
5Bi
nax
Now
Mal
aria
Tes
t IN
6600
50di
agno
stic
ks- M
alar
ia (P
v/Pf
) Cas
sette
KM
VFC
6002
SD B
IOLI
NE
Mal
aria
Ag
Pf/ P
an 0
5FK6
6C
areS
tart
Mal
aria
HR
P2/p
LDH
(Pf/P
v) C
OM
BO G
0161
Med
isen
sor M
alar
ia H
RP2
/pLD
H (P
f/Pv)
CO
MBO
M16
1Pa
raC
are
Mal
aria
HR
P2/p
LDH
(Pf/P
v) C
OM
BO G
0161
HiS
ens
Mal
aria
Ag
P.f/V
OM
Com
bo C
ard
HR
3323
HiS
ens
Mal
aria
Ag
P.f/P
.v C
ombo
Car
d H
R31
23W
ondf
o O
ne S
tep
Mal
aria
P.f
Test
W37
-CC
areS
tart
Mal
aria
HR
P2/p
LDH
(Pf/V
OM
) CO
MBO
G01
71M
edis
enso
r Mal
aria
HR
P2/p
LDH
(Pf/V
OM
) CO
MBO
M17
1Pa
raC
are
Mal
aria
HR
P2/p
LDH
(Pf/V
OM
) CO
MBO
G01
71Fi
rstS
ign™
- Pa
raVi
ew-3
(Pan
+Pv+
Pf) M
alar
ia T
est 2
103
CB-
25C
areS
tart™
Mal
aria
pLD
H 3
Lin
e Te
st G
O12
1Tr
usty
™ M
alar
ia A
ntig
en P
.f. te
st A
03-1
1-32
2Tr
usty
™ M
alar
ia A
ntig
en P
.f./p
.v. t
est A
03-1
2-32
2SD
BIO
LIN
E M
alar
ia A
g P.
f. (H
RP2
/pLD
H)
- 05F
K90
Firs
tSig
n™ -
Para
View
(Pan
+Pf)
Mal
aria
Tes
t 210
1CB-
25H
iSen
s M
alar
ia A
g Pf
HR
P2 C
ard
HR
3023
Car
eSta
rt™ M
alar
ia S
cree
n G
O23
1Ad
vanc
ed Q
ualit
y™ O
ne S
tep
Mal
aria
P.f/
P.v
Tri-L
ine
Test
ITP
1100
3 TC
40IC
T D
iagn
ostic
s M
alar
ia P
.f.
ML0
1O
nSite
Pf A
g R
apid
Tes
t R
0114
CBI
ON
OTE
MAL
ARIA
P.f.
Ag
Rap
id T
est K
it R
G19
-11
ABO
N™
Plu
s M
alar
ia P
.f/Pa
n R
apid
Tes
t Dev
ice
(Who
le B
lood
) IM
A-T4
02N
anoS
ign
Mal
aria
Pf A
g R
MAF
10Pa
raH
IT®
- f
(Dev
ice)
55I
C10
2-50
Para
HIT
- To
tal V
er. 1
.0 (D
ipst
ick)
55I
C20
3-10
Mal
eris
can®
Mal
aria
P.f/
PAN
(Pv,
Pm
, Po)
3 L
ine
Antig
en T
est M
AT-P
F/PA
N-5
0Fi
rst R
espo
nse®
Mal
aria
pLD
H/H
RP2
Com
bo T
est I
16FR
C30
HiS
ens
Mal
aria
Ag
Pf/P
v (H
RP2
/pLD
H) C
ard
HR
2923
Cle
arvi
ew®
Mal
aria
P.f.
VB0
1C
areS
tart™
Mal
aria
/Pre
gnan
cy C
ombo
(pLD
H/H
RP2
/HC
G)
GO
221
Sure
step
™ E
asy
Mal
aria
Pf/P
an R
apid
Tes
t Dev
ice
IMA-
T402
Mal
eris
can®
Mal
aria
P.f
Antig
en T
est M
AT-P
F-50
Cle
arvi
ew®
Mal
aria
Com
bo V
B11
Mal
asca
n™ D
evic
e - R
apid
test
for M
alar
ia P
f/Pan
50
4020
25IM
MU
NO
QU
ICK
CO
NTA
CT
falc
ipar
um 0
519K
25C
lear
view
® M
alar
ia p
LDH
708
8402
5Pa
raH
IT®
-f (D
ipst
ick)
55I
c101
-50
diag
nost
icks
- Mal
aria
(Pf)
Dip
stic
k K
MFD
6007
Mal
aria
pf (
HR
P II)
/ pv
(pLD
H) A
ntig
en D
etec
tion
Test
Dev
ice
MFV
-124
VO
nSite
Pf/P
v Ag
Rap
id T
est R
0112
CIC
T D
iagn
ostic
s M
alar
ia D
ual
ML0
3Pa
raH
IT -
Tota
l Ver
. 1.0
(Dev
ice)
55I
C20
4-10
ICT
Dia
gnos
tics
Mal
aria
Com
bo M
L02
EzD
x™ M
alar
ia P
an/P
f Rap
id T
est D
etec
tion
kit R
K M
AL 0
01Ad
vant
age
Mal
aria
Car
d IR
2110
25IM
MU
NO
QU
ICK
CO
NTA
CT
MAL
ARIA
+4
052
5K25
OnS
ite P
f/Pan
Ag
Rap
id T
est
R01
13C
OnS
ight
™ -
Mal
aria
Pf T
est 5
11-2
5-D
BM
alar
ia P
.F/V
ivax
172
11O
P-25
Para
chec
k® P
f - R
apid
test
for P
. fal
cipa
rum
Mal
aria
Dip
stic
k Ve
r.3 3
0302
025
Adva
ntag
e Pa
n M
alar
ia C
ard
IR01
3025
ABO
N M
alar
ia P
an/P
.f. R
apid
Tes
t Dev
ice
IM
A-B4
02C
lear
view
® M
alar
ia D
ual T
est D
evic
e VB
20M
eDiP
ro M
alar
ia A
g H
RP2
/pLD
H C
ombo
IR-0
051K
Para
HIT
® to
tal (
dips
tick)
55I
C20
1-10
Mal
aria
Pf/
PAN
GM
004
AZO
G M
alar
ia p
f (H
RPI
I)/pf
(LD
H)/
(PAN
-LD
H) A
ntig
en D
etec
tion
Dev
ice
MFV
-124
FAd
vant
age
Mal
Car
d IR
2210
25AZ
OG
hC
G M
alar
ia D
etec
tion
Test
Dev
ice
MPT
-124
IND
ON
E ST
EP M
ALAR
IA A
NTI
GEN
P.f
535-
11M
alar
ia p
f (H
RP
II) /
pv (p
LDH
) Ant
igen
Det
ectio
n Te
st D
evic
e 1-
13-1
01-3
OnS
ight
™ –
Par
aQui
ck (P
an, P
f) Te
st 5
36-2
5DB
diag
nost
icks
- Mal
aria
(Pf)
Cas
sette
KM
FC60
01Ad
vanc
ed Q
ualit
y™ M
alar
ia (
p.f)
POC
T IT
P110
02TC
1M
alar
ia P
an T
est
MAL
-W23
N-0
01M
aler
isca
n® M
alar
ia P
f/Pv
MAT
-50
One
Ste
p M
alar
ia P
.F/P
.V T
est (
Cas
sette
) 523
352
Opt
iMAL
-IT 7
1002
4Fi
rstS
ign™
- Pa
raVi
ew-2
(Pv
+ Pf
) Car
d Te
st 2
102C
B-25
Hex
agon
Mal
aria
Com
bi 5
8024
Mal
aria
Pf/P
v G
M00
2M
alar
ia p
f (H
RP
II)/P
AN (p
LDH
) Ant
igen
Det
ectio
n Te
st D
evic
e 1-
13-1
01-1
Hex
agon
Mal
aria
580
51O
ne S
tep
Mal
aria
P.f/
Pan
Test
W
56-C
Para
hit-T
otal
Dev
ice
Rap
id te
st fo
r P. f
alci
paru
m a
nd P
an m
alar
ial s
peci
es. 2
5989
ABO
N™
Mal
aria
P.f.
Rap
id T
est D
evic
e (W
hole
Blo
od) I
MA-
402
Firs
tSig
n™ -
Mal
aria
Pf C
ard
Test
Firs
t Res
pons
e® M
alar
ia A
g pL
DH
I12F
RC
30Fi
rstS
ign™
- Pa
nChe
ck (P
an) M
alar
ia T
est 2
104
CB-
25O
nSig
ht™
- Pa
nScr
een
(Pan
) Mal
aria
Tes
t 539
-25-
DB
HiS
ens
Mal
aria
Ag
P.f/P
.v C
ard
HR
2823
Para
bank
™ D
evic
e - R
apid
test
for M
alar
ia P
an
5030
1025
SD B
IOLI
NE
Mal
aria
Ag
05F
K40
diag
nost
icks
MAL
ARIA
(Pan
) Cas
sette
MPN
WBC
1007
.3N
anoS
ign
Mal
aria
Pf/P
v Ag
RM
AD10
Mal
aria
pf (
pLD
H) /
PAN
-pLD
H T
est D
evic
e
MFV
-124
One
Ste
p M
alar
ia A
ntig
en S
trip
820-
1Q
uick
stic
k M
alar
ia A
ntig
en T
est
200 parasites/µl (HRP2)
200 parasites/µl (non-HRP2)
2000 parasites/µl (HRP2)
2000 parasites/µl (non-HRP2)
False-positive Plasmodium spp. rate (%)Invalid rate (%)
sUM
Mar
Y r
oU
nd
s 1-
4
5Malaria rapid diagnostic test perforMance – summary results of WHo product testing of malaria rdts: round 1-4 (2008-2012)
Figure S1: Malaria RDT performance in Phase 2 of Rounds 1-4 against wild type (clinical) samples containing P. falciparum at low (200) and high (2000–5000) parasite densities (parasites/µl) and clean-negative samples
a Panel detection score - A sample is considered detected only if all RDTs from both lots read by the first technician, at minimum specified reading time, are positive. b Clean-negative - blood samples from healthy volunteers with no known current illness or blood abnormality. * Indicates tests that also detect other non-P. falciparum parasites
Firs
t Res
pons
e® M
alar
ia A
g H
RP2
I13
FRC
30H
umas
is M
alar
ia P
.f/Pa
n An
tigen
Tes
t AM
AL-7
025
Para
scre
en™
Dev
ice
- Rap
id te
st f
or M
alar
ia P
an/P
f 503
1002
5C
ore
Mal
aria
Pan
Pf M
AL-1
9002
4BI
OC
RED
IT M
alar
ia p
f(HR
P II)
HR
0100
Car
eSta
rt™ M
alar
ia H
RP2
(Pf)
G01
41C
areS
tart™
Mal
aria
HR
P2/p
LDH
Pf t
est G
0181
Falc
ivax
™ R
apid
Tes
t for
Mal
aria
Pv/
Pf 5
0300
025
diag
nost
icks
MAL
ARIA
(Pan
/Pf)
Cas
sette
MPN
FWBC
1007
.4C
ore™
Mal
aria
Pv/
Pf M
AL-1
9002
2Ad
vant
age
P.f.
Mal
aria
Car
d IR
0160
25C
areS
tart™
Mal
aria
HR
P2/p
LDH
(Pf/P
AN) C
OM
BO G
0131
SD B
IOLI
NE
Mal
aria
Ag
Pf 0
5FK5
0C
ore™
Mal
aria
Pf
MAL
-190
020
SD B
IOLI
NE
Mal
aria
Ag
Pf/ P
f/ Pv
05F
K100
SD B
IOLI
NE
Mal
aria
Ag
Pf/P
v 05
FK80
Para
chec
k® P
f - R
apid
test
for P
. fal
cipa
rum
Mal
aria
Dev
ice
Ver.3
303
0102
5M
alar
ia p
f (H
RP
II) /
(PAN
-pLD
H) A
ntig
en D
etec
tion
Test
Dev
ice
MFV
-124
RIN
D O
NE
STEP
MAL
ARIA
AN
TIG
EN P
.f/Pa
n TE
ST 5
35-1
0Fi
rstS
ign™
Mal
aria
Pf 2
100C
B-25
One
Ste
p M
alar
ia P
.F T
est (
cass
ette
) 5
2235
2Ad
vanc
ed Q
ualit
y™ O
ne S
tep
Mal
aria
P.f
Test
ITP
1100
2TC
40BI
ON
OTE
MAL
ARIA
P.f.
& Pa
n Ag
Rap
id T
est K
it R
G19
-08
diag
nost
icks
MAL
ARIA
(Pan
/Pv/
Pf) C
asse
tte M
PNVF
C10
07.5
Imm
unoq
uick
Mal
aria
+4
0506
_K25
Para
max
-3 R
apid
Tes
t for
Mal
aria
Pan
/Pv/
Pf (d
evic
e) 5
0320
025
SD B
IOLI
NE
Mal
aria
Ag
P.f/P
an
05FK
60C
ore™
Mal
aria
Pan
/Pv/
Pf M
AL-1
9002
6BI
ON
OTE
MAL
ARIA
P.f.
& P.
v. A
g R
apid
Tes
t Kit
RG
19-1
2N
anoS
ign
Mal
aria
Pf/P
an A
g 3.
0 R
MAP
10H
umas
is M
alar
ia P
.f/P.
v An
tigen
Tes
t AM
FV-7
025
RAP
ID 1
-2-3
® H
EMA
CAS
SETT
E M
ALAR
IA P
F/PV
TES
T M
AL-P
FV-C
AS/2
5(10
0)M
alar
ia P
lasm
odiu
m fa
lcip
arum
Rap
id te
st D
evic
e (W
hole
blo
od) I
MA-
402
Car
eSta
rt™ M
alar
ia p
LDH
(PAN
) G01
11O
nSig
ht™
- Pa
raQ
uick
-2 (P
v,Pf
) Mal
aria
Tes
t 537
-25-
DB
Imm
unoq
uick
Mal
aria
Fal
cipa
rum
050
2_K2
5Bi
nax
Now
Mal
aria
Tes
t IN
6600
50di
agno
stic
ks- M
alar
ia (P
v/Pf
) Cas
sette
KM
VFC
6002
SD B
IOLI
NE
Mal
aria
Ag
Pf/ P
an 0
5FK6
6C
areS
tart
Mal
aria
HR
P2/p
LDH
(Pf/P
v) C
OM
BO G
0161
Med
isen
sor M
alar
ia H
RP2
/pLD
H (P
f/Pv)
CO
MBO
M16
1Pa
raC
are
Mal
aria
HR
P2/p
LDH
(Pf/P
v) C
OM
BO G
0161
HiS
ens
Mal
aria
Ag
P.f/V
OM
Com
bo C
ard
HR
3323
HiS
ens
Mal
aria
Ag
P.f/P
.v C
ombo
Car
d H
R31
23W
ondf
o O
ne S
tep
Mal
aria
P.f
Test
W37
-CC
areS
tart
Mal
aria
HR
P2/p
LDH
(Pf/V
OM
) CO
MBO
G01
71M
edis
enso
r Mal
aria
HR
P2/p
LDH
(Pf/V
OM
) CO
MBO
M17
1Pa
raC
are
Mal
aria
HR
P2/p
LDH
(Pf/V
OM
) CO
MBO
G01
71Fi
rstS
ign™
- Pa
raVi
ew-3
(Pan
+Pv+
Pf) M
alar
ia T
est 2
103
CB-
25C
areS
tart™
Mal
aria
pLD
H 3
Lin
e Te
st G
O12
1Tr
usty
™ M
alar
ia A
ntig
en P
.f. te
st A
03-1
1-32
2Tr
usty
™ M
alar
ia A
ntig
en P
.f./p
.v. t
est A
03-1
2-32
2SD
BIO
LIN
E M
alar
ia A
g P.
f. (H
RP2
/pLD
H)
- 05F
K90
Firs
tSig
n™ -
Para
View
(Pan
+Pf)
Mal
aria
Tes
t 210
1CB-
25H
iSen
s M
alar
ia A
g Pf
HR
P2 C
ard
HR
3023
Car
eSta
rt™ M
alar
ia S
cree
n G
O23
1Ad
vanc
ed Q
ualit
y™ O
ne S
tep
Mal
aria
P.f/
P.v
Tri-L
ine
Test
ITP
1100
3 TC
40IC
T D
iagn
ostic
s M
alar
ia P
.f.
ML0
1O
nSite
Pf A
g R
apid
Tes
t R
0114
CBI
ON
OTE
MAL
ARIA
P.f.
Ag
Rap
id T
est K
it R
G19
-11
ABO
N™
Plu
s M
alar
ia P
.f/Pa
n R
apid
Tes
t Dev
ice
(Who
le B
lood
) IM
A-T4
02N
anoS
ign
Mal
aria
Pf A
g R
MAF
10Pa
raH
IT®
- f
(Dev
ice)
55I
C10
2-50
Para
HIT
- To
tal V
er. 1
.0 (D
ipst
ick)
55I
C20
3-10
Mal
eris
can®
Mal
aria
P.f/
PAN
(Pv,
Pm
, Po)
3 L
ine
Antig
en T
est M
AT-P
F/PA
N-5
0Fi
rst R
espo
nse®
Mal
aria
pLD
H/H
RP2
Com
bo T
est I
16FR
C30
HiS
ens
Mal
aria
Ag
Pf/P
v (H
RP2
/pLD
H) C
ard
HR
2923
Cle
arvi
ew®
Mal
aria
P.f.
VB0
1C
areS
tart™
Mal
aria
/Pre
gnan
cy C
ombo
(pLD
H/H
RP2
/HC
G)
GO
221
Sure
step
™ E
asy
Mal
aria
Pf/P
an R
apid
Tes
t Dev
ice
IMA-
T402
Mal
eris
can®
Mal
aria
P.f
Antig
en T
est M
AT-P
F-50
Cle
arvi
ew®
Mal
aria
Com
bo V
B11
Mal
asca
n™ D
evic
e - R
apid
test
for M
alar
ia P
f/Pan
50
4020
25IM
MU
NO
QU
ICK
CO
NTA
CT
falc
ipar
um 0
519K
25C
lear
view
® M
alar
ia p
LDH
708
8402
5Pa
raH
IT®
-f (D
ipst
ick)
55I
c101
-50
diag
nost
icks
- Mal
aria
(Pf)
Dip
stic
k K
MFD
6007
Mal
aria
pf (
HR
P II)
/ pv
(pLD
H) A
ntig
en D
etec
tion
Test
Dev
ice
MFV
-124
VO
nSite
Pf/P
v Ag
Rap
id T
est R
0112
CIC
T D
iagn
ostic
s M
alar
ia D
ual
ML0
3Pa
raH
IT -
Tota
l Ver
. 1.0
(Dev
ice)
55I
C20
4-10
ICT
Dia
gnos
tics
Mal
aria
Com
bo M
L02
EzD
x™ M
alar
ia P
an/P
f Rap
id T
est D
etec
tion
kit R
K M
AL 0
01Ad
vant
age
Mal
aria
Car
d IR
2110
25IM
MU
NO
QU
ICK
CO
NTA
CT
MAL
ARIA
+4
052
5K25
OnS
ite P
f/Pan
Ag
Rap
id T
est
R01
13C
OnS
ight
™ -
Mal
aria
Pf T
est 5
11-2
5-D
BM
alar
ia P
.F/V
ivax
172
11O
P-25
Para
chec
k® P
f - R
apid
test
for P
. fal
cipa
rum
Mal
aria
Dip
stic
k Ve
r.3 3
0302
025
Adva
ntag
e Pa
n M
alar
ia C
ard
IR01
3025
ABO
N M
alar
ia P
an/P
.f. R
apid
Tes
t Dev
ice
IM
A-B4
02C
lear
view
® M
alar
ia D
ual T
est D
evic
e VB
20M
eDiP
ro M
alar
ia A
g H
RP2
/pLD
H C
ombo
IR-0
051K
Para
HIT
® to
tal (
dips
tick)
55I
C20
1-10
Mal
aria
Pf/
PAN
GM
004
AZO
G M
alar
ia p
f (H
RPI
I)/pf
(LD
H)/
(PAN
-LD
H) A
ntig
en D
etec
tion
Dev
ice
MFV
-124
FAd
vant
age
Mal
Car
d IR
2210
25AZ
OG
hC
G M
alar
ia D
etec
tion
Test
Dev
ice
MPT
-124
IND
ON
E ST
EP M
ALAR
IA A
NTI
GEN
P.f
535-
11M
alar
ia p
f (H
RP
II) /
pv (p
LDH
) Ant
igen
Det
ectio
n Te
st D
evic
e 1-
13-1
01-3
OnS
ight
™ –
Par
aQui
ck (P
an, P
f) Te
st 5
36-2
5DB
diag
nost
icks
- Mal
aria
(Pf)
Cas
sette
KM
FC60
01Ad
vanc
ed Q
ualit
y™ M
alar
ia (
p.f)
POC
T IT
P110
02TC
1M
alar
ia P
an T
est
MAL
-W23
N-0
01M
aler
isca
n® M
alar
ia P
f/Pv
MAT
-50
One
Ste
p M
alar
ia P
.F/P
.V T
est (
Cas
sette
) 523
352
Opt
iMAL
-IT 7
1002
4Fi
rstS
ign™
- Pa
raVi
ew-2
(Pv
+ Pf
) Car
d Te
st 2
102C
B-25
Hex
agon
Mal
aria
Com
bi 5
8024
Mal
aria
Pf/P
v G
M00
2M
alar
ia p
f (H
RP
II)/P
AN (p
LDH
) Ant
igen
Det
ectio
n Te
st D
evic
e 1-
13-1
01-1
Hex
agon
Mal
aria
580
51O
ne S
tep
Mal
aria
P.f/
Pan
Test
W
56-C
Para
hit-T
otal
Dev
ice
Rap
id te
st fo
r P. f
alci
paru
m a
nd P
an m
alar
ial s
peci
es. 2
5989
ABO
N™
Mal
aria
P.f.
Rap
id T
est D
evic
e (W
hole
Blo
od) I
MA-
402
Firs
tSig
n™ -
Mal
aria
Pf C
ard
Test
Firs
t Res
pons
e® M
alar
ia A
g pL
DH
I12F
RC
30Fi
rstS
ign™
- Pa
nChe
ck (P
an) M
alar
ia T
est 2
104
CB-
25O
nSig
ht™
- Pa
nScr
een
(Pan
) Mal
aria
Tes
t 539
-25-
DB
HiS
ens
Mal
aria
Ag
P.f/P
.v C
ard
HR
2823
Para
bank
™ D
evic
e - R
apid
test
for M
alar
ia P
an
5030
1025
SD B
IOLI
NE
Mal
aria
Ag
05F
K40
diag
nost
icks
MAL
ARIA
(Pan
) Cas
sette
MPN
WBC
1007
.3N
anoS
ign
Mal
aria
Pf/P
v Ag
RM
AD10
Mal
aria
pf (
pLD
H) /
PAN
-pLD
H T
est D
evic
e
MFV
-124
One
Ste
p M
alar
ia A
ntig
en S
trip
820-
1Q
uick
stic
k M
alar
ia A
ntig
en T
est
200 parasites/µl (HRP2)
200 parasites/µl (non-HRP2)
2000 parasites/µl (HRP2)
2000 parasites/µl (non-HRP2)
False-positive Plasmodium spp. rate (%)Invalid rate (%)
6 Malaria rapid diagnostic test perforMance – summary results of WHo product testing of malaria rdts: round 1-4 (2008-2012)
Figure S2: Malaria RDT performance in Phase 2 of Rounds 1-4 against wild type (clinical) samples containing P. vivax at low (200) and high (2000–5000) parasite densities (parasites/µl)) and clean-negative samples
a Panel detection score - A sample is considered detected only if all RDTs from both lots read by the first technician, at minimum specified reading time, are positive. b Clean-negative - blood samples from healthy volunteers with no known current illness or blood abnormality.
Hu
mas
is M
alar
ia P
.f/P
.v A
nti
gen
Tes
t A
MF
V-7
02
5O
nS
ite
Pf/
Pv
Ag
Rap
id T
est
R0
11
2C
Ad
van
tag
e P
an M
alar
ia C
ard
IR
01
30
25
Ad
van
tag
e M
al C
ard
IR
22
10
25
Car
eSta
rt™
Mal
aria
pL
DH
(P
AN
) G
01
11
SD
BIO
LIN
E M
alar
ia A
g
05
FK
40
SD
BIO
LIN
E M
alar
ia A
g P
.f/P
an
05
FK
60
BIO
NO
TE
MA
LA
RIA
P.f
.& P
.v.
Ag
Rap
id T
est
Kit
R
G1
9-1
2O
pti
MA
L-I
T
71
00
24
Nan
oS
ign
Mal
aria
Pf/
Pan
Ag
3.0
RM
AP
10
SD
BIO
LIN
E M
alar
ia A
g P
f/ P
f/ P
v 0
5F
K1
00
SD
BIO
LIN
E M
alar
ia A
g P
f/P
v 0
5F
K8
0C
areS
tart
™
Mal
aria
/Pre
gn
ancy
Co
mb
o (
pL
DH
/HR
P2
/HC
G)
GO
22
1C
areS
tart
Mal
aria
HR
P2
/pL
DH
(P
f/P
v) C
OM
BO
G0
16
1M
edis
enso
r M
alar
ia H
RP
2/p
LD
H (
Pf/
Pv)
CO
MB
O M
16
1P
araC
are
Mal
aria
HR
P2
/pL
DH
(P
f/P
v) C
OM
BO
G0
16
1S
D B
IOL
INE
Mal
aria
Ag
Pf/
Pan
05
FK
66
Fir
st R
esp
on
se®
Mal
aria
Ag
pL
DH
I1
2F
RC
30
SD
BIO
LIN
E M
alar
ia A
g P
v 0
5F
K7
0C
areS
tart
™ M
alar
ia p
LD
H 3
Lin
e Te
st
GO
12
1C
areS
tart
™ M
alar
ia H
RP
2/p
LD
H (
Pf/
VO
M)
CO
MB
O G
01
71
Med
isen
sor
Mal
aria
HR
P2
/pL
DH
(P
f/V
OM
) C
OM
BO
M1
71
Par
aCar
e M
alar
ia H
RP
2/p
LD
H (
Pf/
VO
M)
CO
MB
O G
01
71
Car
eSta
rt™
Mal
aria
HR
P2
/pL
DH
(P
f/P
AN
) C
OM
BO
G0
13
1C
areS
tart
™ M
alar
ia S
cree
n
GO
23
1B
ION
OT
E M
AL
AR
IA P
.f.&
Pan
Ag
Rap
id T
est
Kit
R
G1
9-0
8F
alci
vax™
Rap
id T
est
for
Mal
aria
Pv/
Pf
50
30
00
25
On
Sit
e P
f/P
an A
g R
apid
Tes
t R
01
13
CO
ne
Ste
p M
alar
ia P
.f/P
an T
est
W
56
-CC
lear
view
® M
alar
ia p
LD
H 7
08
84
02
5F
irst
Sig
n™
- P
anC
hec
k (P
an)
Mal
aria
Tes
t 2
10
4 C
B-2
5P
araH
IT -
To
tal V
er.
1.0
(D
evic
e) 5
5IC
20
4-1
0R
AP
ID 1
-2-3
® H
EM
A C
AS
SE
TTE
MA
LAR
IA P
F/P
V T
ES
T M
AL-
PFV
-CA
S/2
5(10
0)H
iSen
s M
alar
ia A
g P
.f/P
.v C
om
bo
Car
d H
R3
12
3O
nS
igh
t™ -
Pan
Scr
een
(P
an)
Mal
aria
Tes
t 5
39
-25
-DB
HiS
ens
Mal
aria
Ag
P.f
/VO
M C
om
bo
Car
d H
R3
32
3F
irst
Res
po
nse
® M
alar
ia p
LD
H/H
RP
2 C
om
bo
Tes
t I1
6F
RC
30
HiS
ens
Mal
aria
Ag
Pf/
Pv
(HR
P2
/pL
DH
) C
ard
HR
29
23
Par
aban
k™ D
evic
e -
Rap
id t
est
for
Mal
aria
Pan
5
03
01
02
5F
irst
Sig
n™
- P
araV
iew
(P
an+
Pf)
Mal
aria
Tes
t 2
10
1C
B-2
5P
araH
IT -
To
tal V
er.
1.0
(D
ipst
ick)
55
IC2
03
-10
IND
ON
E S
TE
P M
AL
AR
IA A
NT
IGE
N P
.f/P
an T
ES
T 5
35
-10
ICT
Dia
gn
ost
ics
Mal
aria
Du
al
ML
03
Co
re™
M
alar
ia P
v/P
f M
AL
-19
00
22
Mal
asca
n™
Dev
ice
- R
apid
tes
t fo
r M
alar
ia P
f/P
an
50
40
20
25
dia
gn
ost
icks
MA
LA
RIA
(P
an)
Cas
sett
e M
PN
WB
C1
00
7.3
dia
gn
ost
icks
MA
LA
RIA
(P
an/P
f) C
asse
tte
MP
NF
WB
C1
00
7.4
On
Sig
ht™
Par
aQu
ick
(Pan
, P
f) T
est
53
6-2
5D
BC
lear
view
® M
alar
ia D
ual
Tes
t D
evic
e V
B2
0d
iag
no
stic
ks-
Mal
aria
(P
v/P
f) C
asse
tte
KM
VF
C6
00
2F
irst
Sig
n™
- P
araV
iew
-3 (
Pan
+P
v+P
f) M
alar
ia T
est
21
03
CB
-25
Par
amax
-3 R
apid
Tes
t fo
r M
alar
ia P
an/P
v/P
f (d
evic
e) 5
03
20
02
5Tr
ust
y™ M
alar
ia A
nti
gen
P.f
./p
.v.
test
A0
3-1
2-3
22
On
Sig
ht™
- P
araQ
uic
k-2
(P
v,P
f) M
alar
ia T
est
53
7-2
5-D
BA
dva
nta
ge
Mal
aria
Car
d
IR2
11
02
5Im
mu
no
qu
ick
Mal
aria
+4
05
06
_K2
5C
ore
Mal
aria
Pan
Pf
MA
L-1
90
02
4P
aras
cree
n®
Dev
ice
- R
apid
tes
t f
or
Mal
aria
Pan
/Pf
50
31
00
25
IMM
UN
OQ
UIC
K C
ON
TAC
T M
AL
AR
IA +
4
05
25
K2
5H
iSen
s M
alar
ia A
g P
.f/P
.v C
ard
H
R2
82
3E
zDx™
Mal
aria
Pan
/Pf
Rap
id T
est
Det
ecti
on
kit
RK
MA
L 0
01
Co
re™
M
alar
ia P
an/P
v/P
f M
AL
-19
00
26
dia
gn
ost
icks
MA
LA
RIA
(P
an/P
v/P
f) C
asse
tte
MP
NV
FC
10
07
.5P
araH
IT®
to
tal (
dip
stic
k) 5
5IC
20
1-1
0B
inax
No
w
Mal
aria
Tes
t IN
66
00
50
Nan
oS
ign
Mal
aria
Pf/
Pv
Ag
RM
AD
10
AB
ON
™ P
lus
Mal
aria
P.f
/Pan
Rap
id T
est
Dev
ice
(Wh
ole
Blo
od
) IM
A-T
40
2IC
T M
alar
ia C
om
bo
M
L0
2M
alar
ia p
f (p
LD
H)
/ P
AN
-pL
DH
Tes
t D
evic
e
MF
V-1
24
Cle
arvi
ew®
Mal
aria
Co
mb
o V
B1
1M
alar
ia P
f/ P
AN
GM
00
4M
alar
ia p
f (H
RP
II)/
PA
N (
pL
DH
) A
nti
gen
Det
ecti
on
Tes
t D
evic
e 1
-13
-10
1-1
MeD
iPro
Mal
aria
Ag
HR
P2
/pL
DH
Co
mb
o I
R-0
05
1K
Su
rest
ep™
Eas
y M
alar
ia P
f/P
an R
apid
Tes
t D
evic
e I
MA
-T4
02
Mal
aria
pf
(HR
P I
I) /
(PA
N-p
LD
H)
An
tig
en D
etec
tio
n T
est
Dev
ice
M
FV
-12
4R
On
e S
tep
Mal
aria
P.F
/P.V
Tes
t (C
asse
tte)
52
33
52
AZ
OG
Mal
aria
pf
(HR
PII)
/pf
(LD
H)/
(P
AN
-LD
H)
An
tig
en D
etec
tio
n D
evic
e M
FV
-12
4F
Fir
stS
ign
™ -
Par
aVie
w-2
(P
v +
Pf)
Car
d T
est
21
02
CB
-25
Mal
eris
can
® M
alar
ia P
.f/P
AN
(P
v, P
m,
Po
) 3
Lin
e A
nti
gen
Tes
t M
AT-
PF
/PA
N-5
0A
BO
N M
alar
ia P
an/P
.f.
Rap
id T
est
Dev
ice
IM
A-B
40
2M
aler
isca
n®
Mal
aria
Pf/
Pv
MA
T-5
0O
ne
Ste
p M
alar
ia A
nti
gen
Str
ip 8
20
-1Q
uic
ksti
ck M
alar
ia A
nti
gen
Tes
tA
ZO
G
hC
G M
alar
ia D
etec
tio
n T
est
Dev
ice
MP
T-1
24
Par
ahit
-To
tal D
evic
e R
apid
tes
t fo
r P.
fal
cip
aru
m a
nd
Pan
mal
aria
l sp
ecie
s. 2
59
89
Hex
ago
n M
alar
ia C
om
bi 5
80
24
Mal
aria
Pan
Tes
t M
AL
-W2
3N
-00
1M
alar
ia P
.F/V
ivax
17
21
1O
P-2
5M
alar
ia p
f (H
RP
II)
/ p
v (p
LD
H)
An
tig
en D
etec
tio
n T
est
Dev
ice
1-1
3-1
01
-3M
alar
ia p
f (H
RP
II)
/ p
v (p
LD
H)
An
tig
en D
etec
tio
n T
est
Dev
ice
MF
V-1
24
VM
alar
ia P
f/P
v G
M0
02
Ad
van
ced
Qu
alit
y™
On
e S
tep
Mal
aria
P.f
/P.v
Tri
-Lin
e Te
st
ITP
11
00
3 T
C4
0H
um
asis
Mal
aria
P.f
/Pan
An
tig
en T
est
AM
AL
-70
25
sUM
Mar
Y r
oU
nd
s 1-
4
7Malaria rapid diagnostic test perforMance – summary results of WHo product testing of malaria rdts: round 1-4 (2008-2012)
Figure S2: Malaria RDT performance in Phase 2 of Rounds 1-4 against wild type (clinical) samples containing P. vivax at low (200) and high (2000–5000) parasite densities (parasites/µl)) and clean-negative samples
a Panel detection score - A sample is considered detected only if all RDTs from both lots read by the first technician, at minimum specified reading time, are positive. b Clean-negative - blood samples from healthy volunteers with no known current illness or blood abnormality.
Hu
mas
is M
alar
ia P
.f/P
.v A
nti
gen
Tes
t A
MF
V-7
02
5O
nS
ite
Pf/
Pv
Ag
Rap
id T
est
R0
11
2C
Ad
van
tag
e P
an M
alar
ia C
ard
IR
01
30
25
Ad
van
tag
e M
al C
ard
IR
22
10
25
Car
eSta
rt™
Mal
aria
pL
DH
(P
AN
) G
01
11
SD
BIO
LIN
E M
alar
ia A
g
05
FK
40
SD
BIO
LIN
E M
alar
ia A
g P
.f/P
an
05
FK
60
BIO
NO
TE
MA
LA
RIA
P.f
.& P
.v.
Ag
Rap
id T
est
Kit
R
G1
9-1
2O
pti
MA
L-I
T
71
00
24
Nan
oS
ign
Mal
aria
Pf/
Pan
Ag
3.0
RM
AP
10
SD
BIO
LIN
E M
alar
ia A
g P
f/ P
f/ P
v 0
5F
K1
00
SD
BIO
LIN
E M
alar
ia A
g P
f/P
v 0
5F
K8
0C
areS
tart
™
Mal
aria
/Pre
gn
ancy
Co
mb
o (
pL
DH
/HR
P2
/HC
G)
GO
22
1C
areS
tart
Mal
aria
HR
P2
/pL
DH
(P
f/P
v) C
OM
BO
G0
16
1M
edis
enso
r M
alar
ia H
RP
2/p
LD
H (
Pf/
Pv)
CO
MB
O M
16
1P
araC
are
Mal
aria
HR
P2
/pL
DH
(P
f/P
v) C
OM
BO
G0
16
1S
D B
IOL
INE
Mal
aria
Ag
Pf/
Pan
05
FK
66
Fir
st R
esp
on
se®
Mal
aria
Ag
pL
DH
I1
2F
RC
30
SD
BIO
LIN
E M
alar
ia A
g P
v 0
5F
K7
0C
areS
tart
™ M
alar
ia p
LD
H 3
Lin
e Te
st
GO
12
1C
areS
tart
™ M
alar
ia H
RP
2/p
LD
H (
Pf/
VO
M)
CO
MB
O G
01
71
Med
isen
sor
Mal
aria
HR
P2
/pL
DH
(P
f/V
OM
) C
OM
BO
M1
71
Par
aCar
e M
alar
ia H
RP
2/p
LD
H (
Pf/
VO
M)
CO
MB
O G
01
71
Car
eSta
rt™
Mal
aria
HR
P2
/pL
DH
(P
f/P
AN
) C
OM
BO
G0
13
1C
areS
tart
™ M
alar
ia S
cree
n
GO
23
1B
ION
OT
E M
AL
AR
IA P
.f.&
Pan
Ag
Rap
id T
est
Kit
R
G1
9-0
8F
alci
vax™
Rap
id T
est
for
Mal